Autonomic, neuroendocrine, and immunological effects of ayahuasca: A comparative study with d-amphetamine

Journal of Clinical Psychopharmacology

Volumn 31, Issue 6, 2011, Pages 717-726

  Dos Santos, Rafael G ^a,b   Valle, Marta ^a,b,c   Bouso, José Carlos ^a,b   Nomdedéu, Josep F ^d   Rodríguez Espinosa, José ^a   McIlhenny, Ethan H ^e   Barker, Steven A ^e   Barbanoj, Manel J ^a,b   Riba, Jordi ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Pharmacokinetic and Pharmacodynamic Modelling and Simulation ^*  (Spain)

^d Servei Laboratori d'Hematologia   (Spain)

^e LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

autonomic; ayahuasca; immunity; neuroendocrine

Indexed keywords

AMPHETAMINE; GROWTH HORMONE; HYDROCORTISONE; MORPHINE; N,N DIMETHYLTRYPTAMINE; PLACEBO; PROLACTIN;

ADULT; AFFECT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; AYAHUASCA; BODY TEMPERATURE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; IMMUNOMODULATION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; MALE; NATURAL KILLER CELL; NEUROENDOCRINE SYSTEM; PERCEPTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PUPIL; RANDOMIZED CONTROLLED TRIAL; TEA;

ADMINISTRATION, ORAL; ADULT; BANISTERIOPSIS; CROSS-OVER STUDIES; DEXTROAMPHETAMINE; DOUBLE-BLIND METHOD; HALLUCINOGENS; HUMANS; IMMUNITY, CELLULAR; MALE; N,N-DIMETHYLTRYPTAMINE; PLANT EXTRACTS; PROLACTIN; TIME FACTORS; YOUNG ADULT;

EID: 80755129122     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31823607f6     Document Type: Article

References (56)

1. Schultes RE, Hofmann A. The Botany and Chemistry of Hallucinogens. Springfield, IL: Charles C. Thomas; 1980.
2. Schultes RE, Hofmann A. Plants of the Gods: Origins of Hallucinogenic Use. New York: A. van der Marck Editions; 1987.
3. Riba J. Human Pharmacology of Ayahuasca [doctoral thesis]. Universitat Autònoma de Barcelona, 2003. Available at: http://www.tdx.cesca.es/TDX- 0701104-165104/. Accessed April 28, 2011.
4. Buckholtz NS, Boggan WO. Monoamine oxidase inhibition in brain and liver produced by A-carbolines: structure-activity relationships and substrate specificity. Biochem Pharmacol. 1977;26:1991-1996. (Pubitemid 8157980)
5. McKenna DJ, Towers GHN, Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and A-carboline constituents of ayahuasca. J Ethnopharmacol. 1984;10:195-223. (Pubitemid 14081500)
6. Glennon RA, Dukat M, Grella B, et al. Binding of A-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend. 2000;60:121-132. (Pubitemid 30625015)
7. Pierce PA, Peroutka SJ. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology. 1989;97:118-122. (Pubitemid 19020394)
8. McKenna DJ, Repke DB, Lo L, et al. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology. 1990;29:193-198. (Pubitemid 20096380)
9. Strassman RJ, Qualls CR, Uhlenhuth EH, et al. Dose-response study of N,N-dimethyltryptamine in humans, II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51:98-108. (Pubitemid 24054311)
10. Riba J, Valle M, Urbano G, et al. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther. 2003;306:73-83. (Pubitemid 36734359)
11. Tupper KW. The globalization of ayahuasca: harm reduction or benefit maximization. Int J Drug Policy. 2008;19:297-303. (Pubitemid 351970227)
12. Labate BC, Rose IS, Santos RG. Ayahuasca Religions: A Comprehensive Bibliography and Critical Essays. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies; 2009.
13. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther. 2004;102:111-129. (Pubitemid 38681011)
14. Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis. 1996;184:86-94. (Pubitemid 26092979)
15. Fábregas JM, González D, Fondevila S, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend. 2010;111:257-261.
16. Riba J, Rodŕguez-Fornells A, Urbano G, et al. Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology. 2001;154:85-95. (Pubitemid 32186519)
17. Riba J, Anderer P, Morte A, et al. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers. Br J Clin Pharmacol. 2002;53:613-628. (Pubitemid 34621787)
18. Riba J, Romero S, Grasa E, et al. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology. 2006;186:93-98. (Pubitemid 43668314)
19. Barbanoj MJ, Riba J, Clos S, et al. Daytime ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology. 2008;196:315-326.
20. Callaway JC, McKenna DJ, Grob CS, et al. Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol. 1999;65: 243-256. (Pubitemid 29336019)
21. Friedman EM, Irwin MR. Modulation of immune cell function by the autonomic nervous system. Pharmacol Ther. 1997;74:27-38. (Pubitemid 27337352)
22. Schaberg T, Theilacker C, Nitschke OT, et al. Lymphocyte subsets in peripheral blood and smoking habits. Lung. 1997;175:387-394. (Pubitemid 27431216)
23. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev. 2003;16:209-219. (Pubitemid 36519808)
24. Davydova SM, Cheido MA, Gevorgyan MM, et al. Effects of 5-HT2A receptor stimulation and blocking on immune response. Bull Exp Biol Med. 2010;150:219-221.
25. Seletti B, Benkelfat C, Blier P, et al. Serotonin1A receptor activation by flesinoxan in humans. Body temperature and neuroendocrine responses. Neuropsychopharmacology. 1995;13:93-104.
26. Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80: 1523-1631.
27. Riba J, Rodŕguez-Fornells A, Strassman RJ, et al. Psychometric assessment of the Hallucinogen Rating Scale. Drug Alcohol Depend. 2001;62:215-223. (Pubitemid 32276069)
28. Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245-258.
29. Lamas X, Farré M, Llorente M, et al. Spanish version of the 49-item short form of the Addiction Research Center Inventory. Drug Alcohol Depend. 1994;35:203-209. (Pubitemid 24186314)
30. Katz B, Mueller K, Helmle H. Binocular eye movement recording with CCD arrays. Neuro-ophthalmology. 1987;7:81-91. (Pubitemid 17092332)
31. Dütsch M, Hilz MJ, Rauhut U, et al. Sympathetic and parasympathetic pupillary dysfunction in familial dysautonomia. J Neurol Sci. 2002;195:77-83. (Pubitemid 34175103)
32. Wilhelm H, Wilhelm B. Clinical applications of pupillography. J Neuroophthalmol. 2003;23:42-49. (Pubitemid 36292815)
33. Bellido M, Rubiol E, Ubeda J, et al. Rapid and simple immunophenotypic characterization of lymphocytes using a new test. Haematologica. 1998;83:681-685. (Pubitemid 28492147)
34. McIlhenny EH, Riba J, Barbanoj MJ, et al. Methodology for and the determination of the major constituents and metabolites of the Amazonian botanical medicine ayahuasca in human urine. Biomed Chromatogr. 2011;25(9):970-984.
35. McIlhenny EH, Riba J, Barbanoj MJ, et al. Methodology for determining major constituents of ayahuasca and their metabolites in blood. Biomed Chromatrogr. 2011 [Epub ahead of print]. Doi: 10.1002/bmc.1657.
36. Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans, I. Neuroendocrine, autonomic and cardiovascular effects. Arch Gen Psychiatry. 1994;51:85-97. (Pubitemid 24054310)
37. Strassman RJ, Qualls CR, Berg LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry. 1996;39: 784-795. (Pubitemid 26156742)
38. Rosenberg DE, Isbell H, Miner EJ. Comparison of a placebo, N-dimethyltryptamine and 6-hydroxy-N-dimethyltryptamine in man. Psychopharmacologia. 1963;4:39-42.
39. Rosenberg DE, Isbell H, Miner EJ, et al. The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacologia. 1964;5:217-227.
40. Mas M, Farré M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136-145. (Pubitemid 29302313)
41. de la Torre R, Farré M, Roset PN, et al. Pharmacology of MDMA in humans. Ann N Y Acad Sci. 2000;914:225-237.
42. Bitsios P, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology. 1999;143:286-292. (Pubitemid 29204983)
43. Siepmann T, Ziemssen T, Mueck-Weymann M, et al. The effects of venlafaxine on autonomic functions in healthy volunteers. J Clin Psychopharmacol. 2007;27:687-691. (Pubitemid 351339458)
44. Flory JD, Manuck SB, Perel JM, et al. A comparison of D,L-fenfluramine and citalopram challenges in healthy adults. Psychopharmacology. 2004;174:376-380. (Pubitemid 39044295)
45. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(suppl 2):12-19.
46. Armario A. Activation of the hypothalamic-pituitary-adrenal axis by addictive drugs: different pathways, common outcome. Trends Pharmacol Sci. 2010;31:318-325.
47. Pacifici R, Zuccaro P, Farré M, et al. Immunomodulating activity of MDMA. Ann N Y Acad Sci. 2000;914:215-224.
48. Pacifici R, Zuccaro P, Hernandez López C, et al. Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther. 2001;296:207-215. (Pubitemid 32015080)
49. Irwin MR, Olmos L, Wang M, et al. Cocaine dependence and acute cocaine induce decreases of monocyte proinflammatory cytokine expression across the diurnal period: autonomic mechanisms. J Pharmacol Exp Ther. 2007;320:507-515. (Pubitemid 46151073)
50. Pacifici R, Zuccaro P, Farré M, et al. Combined immunomodulating properties of 3,4-methylenedioxymethamphetamine (MDMA) and cannabis in humans. Addiction. 2007;102:931-936. (Pubitemid 46802231)
51. Chaplin DD. Overviewof the immune response. J Allergy Clin Immunol. 2010;125(2 suppl 2):S3YS23.
52. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-469.
53. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol. 2008;8:259-268. (Pubitemid 351432802)
54. Breznitz S, Ben-Zur H, Berzon Y, et al. Experimental induction and termination of acute psychological stress in human volunteers: effects on immunological, neuroendocrine, cardiovascular, and psychological parameters. Brain Behav Immun. 1998;12:34-52. (Pubitemid 29012193)
55. Van de Kar LD, Blair ML. Forebrain pathways mediating stress-induced hormone secretion. Front Neuroendocrinol. 1999;20:1-48. (Pubitemid 29053102)
56. Dhabhar FS. Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology. Neuroimmunomodulation. 2009;16:300-317.